Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
Press Releases
24 October 2023
Crescendo Biologics to participate in upcoming investor and partnering conferences
04 September 2023
Crescendo Biologics wins significant European Patent Office ruling related to the engineering of immunoglobulin technology
24 July 2023
Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
15 March 2023
Crescendo Biologics announces presentation at AACR 2023
31 January 2023
Crescendo Biologics is category winner for Biopharma and Vaccines
in 2023 UK DIT Life Sciences Innovator Showcase
24 January 2023
Crescendo Biologics to participate in upcoming investor conferences